<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922998</url>
  </required_header>
  <id_info>
    <org_study_id>LeukoDx_CD64_AB_sepsis</org_study_id>
    <nct_id>NCT02922998</nct_id>
  </id_info>
  <brief_title>CD64 and Antibiotics in Human Sepsis</brief_title>
  <acronym>CD64SEPLDX</acronym>
  <official_title>Monitoring CD64 on Neutrophils Regarding Effects of Antibiotics in Patients With SIRS Developing Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether CD64 expression on neutrophils measured by a
      new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy
      in critically ill adult patients at risk of sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, in critically ill patients with suspected infection undergoing
      application of antibiotics, CD64 and inflammatory plasma markers will be determined on days 1
      to 4.

      CD64 expression on the surface of neutrophils will be determined by fluorescence activated
      cell sorter (FACS) and with a new bedside test (LeukoDx).

      The purpose of the study is to clarify:

        1. Is CD64 expression on neutrophils associated with effective antibiotic therapy in
           critically ill adult patients at risk of sepsis?

        2. Is CD64 expression associated with distinct plasma parameters of inflammation?

        3. Do the results of the gold standard CD64 determination by FACS correlate with those of a
           new bedside test (LeukoDx)?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD64 expression on neutrophils measured by LeukoDx</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of course of CD64 expression with effective antibiotic treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CD64 expression on neutrophils measured by FACS</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Association of CD64 expression with inflammatory markers</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Association of CD64 expression with cell surface markers on monocytes</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <condition>Critical Illness</condition>
  <condition>SIRS</condition>
  <condition>Sepsis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill adult patients with SIRS at risk of sepsis with suspected infections in whom
        application of antibiotics is started
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  critically ill adult patients

          -  sepsis

          -  SIRS

          -  initiation of antibiotic treatment

          -  patients &lt; 48 hours after admission on ICU

        Exclusion Criteria:

          -  multiple admissions on ICU, (&gt;1 in last 2 weeks period)

          -  leukopenia &lt; 1 G/l

          -  and thrombocytopenia

          -  rhG-CSF or IFN-gamma therapy up to 1 week before inclusion

          -  participation in another study receiving drugs or biological within the preceeding 30
             days

          -  recent longterm corticosteroid treatment

          -  HIV

          -  patients after organ transplantation treated with immunomodulating drugs

          -  pregnant patients or after delivery

          -  life expectancy &lt; 24 hours

          -  polytraumatized patients with reanimation on scene, or infest prognosis

          -  patients under high dose corticosteroids or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, University Hospital Ulm; Ulm, Germany 89075</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manfred Weiss, MD</last_name>
    <phone>49 (0)731-500-60226</phone>
    <email>manfred.weiss@uni-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion E Schneider, PhD</last_name>
    <phone>: 49 (0)731-500-60319</phone>
    <email>marion.schneider@uni-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred E Weiss, MD</last_name>
      <phone>49 (0)731-500-60226</phone>
      <email>manfred.weiss@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth M Schneider, PhD</last_name>
      <phone>49 (0)731-500-60319</phone>
      <email>marion.schneider@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Barth E, Fischer G, Schneider EM, Wollmeyer J, Georgieff M, Weiss M. Differences in the expression of CD64 and mCD14 on polymorphonuclear cells and on monocytes in patients with septic shock. Cytokine. 2001 Jun 7;14(5):299-302.</citation>
    <PMID>11444911</PMID>
  </reference>
  <reference>
    <citation>Barth E, Fischer G, Schneider EM, Moldawer LL, Georgieff M, Weiss M. Peaks of endogenous G-CSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine. 2002 Mar 7;17(5):275-84.</citation>
    <PMID>12027409</PMID>
  </reference>
  <reference>
    <citation>Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wernet P. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care. 1995 Mar;10(1):21-6.</citation>
    <PMID>7538851</PMID>
  </reference>
  <reference>
    <citation>Weiss M, Gross-Weege W, Harms B, Schneider EM. Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine. 1996 Mar;8(3):260-5.</citation>
    <PMID>8833041</PMID>
  </reference>
  <reference>
    <citation>Fischer G, Schneider EM, L Moldawer LL, Karcher C, Barth E, Suger-Wiedeck H, Georgieff M, Weiss M. CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Med. 2001 Dec;27(12):1848-52. Epub 2001 Nov 8.</citation>
    <PMID>11797018</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Manfred Weiss</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>CD64 antigens</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Granulocyte Colony-Stimulating Factor</keyword>
  <keyword>Interleukin-4</keyword>
  <keyword>Interferon-gamma</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>lipopolysaccharide-binding protein</keyword>
  <keyword>procalcitonin</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Patients</keyword>
  <keyword>Human</keyword>
  <keyword>Systemic Inflammatory Response Syndrome</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Infection</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Intensive Care Units</keyword>
  <keyword>Point-of-Care Systems</keyword>
  <keyword>Bedside Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

